Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Peter C Adamson

Showing results (161-170 of 176) with videos related to

Pageof 18
Sort By:
Journal of the National Cancer Institute|October 21, 2004
Treatment of accidental intrathecal methotrexate overdose with intrathecal carboxypeptidase G2Brigitte C Widemann, Frank M Balis, Aiman Shalabi, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 11, 2002
Testing of new agents in childhood cancer preclinical models: meeting summaryPeter J Houghton, Peter C Adamson, Susan Blaney, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 19, 2008
Phase I trial and pharmacokinetic study of bevacizumab in pediatric patients with refractory solid tumors: a Children's Oncology Group StudyJulia L Glade Bender, Peter C Adamson, Joel M Reid, et al.
The New England Journal of Medicine|June 4, 2020
Rituximab for High-Risk, Mature B-Cell Non-Hodgkin's Lymphoma in ChildrenVéronique Minard-Colin, Anne Aupérin, Marta Pillon, et al.
Haematologica|June 24, 2017
Center-level variation in accuracy of adverse event reporting in a clinical trial for pediatric acute myeloid leukemia: a report from the Children's Oncology GroupTamara P Miller, Yimei Li, Marko Kavcic, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 27, 2021
Dose-Adjusted Etoposide, Doxorubicin, and Cyclophosphamide With Vincristine and Prednisone Plus Rituximab Therapy in Children and Adolescents With Primary Mediastinal B-Cell Lymphoma: A Multicenter Phase II TrialG A Amos Burke, Veronique Minard-Colin, Anne Aupérin, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 4, 2022
Reply to R. Lakhotia et alG A Amos Burke, Veronique Minard-Colin, Anne Aupérin, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 18, 2016
Accuracy of Adverse Event Ascertainment in Clinical Trials for Pediatric Acute Myeloid LeukemiaTamara P Miller, Yimei Li, Marko Kavcic, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 29, 2014
Pharmacokinetic and pharmacodynamic properties of calaspargase pegol Escherichia coli L-asparaginase in the treatment of patients with acute lymphoblastic leukemia: results from Children's Oncology Group Study AALL07P4Anne L Angiolillo, Reuven J Schore, Meenakshi Devidas, et al.
European Journal of Cancer (Oxford, England : 1990)|March 15, 2022
ACCELERATE - Five years accelerating cancer drug development for children and adolescentsAndrew D J Pearson, Susan L Weiner, Peter C Adamson, et al.
Pageof 18

Showing results (161-170 of 176) with videos related to

Sort By:
Pageof 18
Journal of the National Cancer Institute|October 21, 2004
Treatment of accidental intrathecal methotrexate overdose with intrathecal carboxypeptidase G2Brigitte C Widemann, Frank M Balis, Aiman Shalabi, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 11, 2002
Testing of new agents in childhood cancer preclinical models: meeting summaryPeter J Houghton, Peter C Adamson, Susan Blaney, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 19, 2008
Phase I trial and pharmacokinetic study of bevacizumab in pediatric patients with refractory solid tumors: a Children's Oncology Group StudyJulia L Glade Bender, Peter C Adamson, Joel M Reid, et al.
The New England Journal of Medicine|June 4, 2020
Rituximab for High-Risk, Mature B-Cell Non-Hodgkin's Lymphoma in ChildrenVéronique Minard-Colin, Anne Aupérin, Marta Pillon, et al.
Haematologica|June 24, 2017
Center-level variation in accuracy of adverse event reporting in a clinical trial for pediatric acute myeloid leukemia: a report from the Children's Oncology GroupTamara P Miller, Yimei Li, Marko Kavcic, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 27, 2021
Dose-Adjusted Etoposide, Doxorubicin, and Cyclophosphamide With Vincristine and Prednisone Plus Rituximab Therapy in Children and Adolescents With Primary Mediastinal B-Cell Lymphoma: A Multicenter Phase II TrialG A Amos Burke, Veronique Minard-Colin, Anne Aupérin, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 4, 2022
Reply to R. Lakhotia et alG A Amos Burke, Veronique Minard-Colin, Anne Aupérin, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 18, 2016
Accuracy of Adverse Event Ascertainment in Clinical Trials for Pediatric Acute Myeloid LeukemiaTamara P Miller, Yimei Li, Marko Kavcic, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 29, 2014
Pharmacokinetic and pharmacodynamic properties of calaspargase pegol Escherichia coli L-asparaginase in the treatment of patients with acute lymphoblastic leukemia: results from Children's Oncology Group Study AALL07P4Anne L Angiolillo, Reuven J Schore, Meenakshi Devidas, et al.
European Journal of Cancer (Oxford, England : 1990)|March 15, 2022
ACCELERATE - Five years accelerating cancer drug development for children and adolescentsAndrew D J Pearson, Susan L Weiner, Peter C Adamson, et al.
Pageof 18